Maize Therapeutics will determine within the next year whether its APOL1 and SLC6A19 programs pass phase two clinical trial scrutiny.
“in the next year or so whether or not its two lead programs, an APOL1 directed kidney drug and another aimed at SLC six a 19, are good enough to pass phase two clinical trial scrutiny”
→ Read the source episode
Our resolution criterion
disputableBoth APOL1 and SLC6A19 programs complete phase two trials and results are publicly disclosed showing whether they met primary endpoints.
More from The Long Run with Luke Timmerman
Matai Mammen predicts Parabolas will eventually conduct a basket trial using a genetic signature to enroll multiple tumor types responsive to zolucatotide
Matai Mammen predicts Parabolas will initiate Phase 3 trials for zolucatotide in desmoid tumors in H1 2027
Maize Therapeutics will have initiated a pivotal study on APOL1 and advanced other programs through mid-stage development by August 2027.
Heather Turner predicts LB Pharma will be on the cusp of schizophrenia approval, have successful bipolar depression phase three data, and positive phase two adjunctive MDD data by 2029.
Avalon will initiate Phase 3 trials for APL1 and APO2 following Phase 2 data readouts in 2027
Heather Turner predicts LB102 will demonstrate efficacy across multiple serious neuropsychiatric indications beyond schizophrenia.
Summaries are ours; the quote is a verbatim transcript excerpt. Our resolution criteria are editorial and disputable. How this works.